Takeda Pharmaceutical Company Limited TAK
Set alert
20.89 USD +0.01 +0.05%
As of Nov 3, 9:59 AM ET
20.78 Day range 20.90
13.50 52-week range 21.22
- YTD
- +34.00%
- 1 year
- +55.66%
- Open
- 20.78
- Prev close
- 20.88
- Mkt cap
- 66.74B
- Vol
- 173.10K
- Avg vol
- 2.73M
- EPS
- 0.07
- P/E
- 298.43
- Div yield
- 2.41%
More statistics
- Low
- 20.78
- High
- 20.90
- Forward P/E
- 39.40
- Beta
- 0.08
- Short ratio
- 1.21
- Inst. own
- 3.32%
- Dividend
- 0.62
- Ex-div date
- Mar 30, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 18.84
- 200-d avg
- 17.55
- 1y target
- 23.02
MAX chart
Events in this range
- Oct 7, 2021Downgrade: Morgan Stanley · Overweight → Equal-Weight
- Apr 4, 2023Rating: TD Cowen · — → Outperform
Signals (97)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| SMA: Bullish | Mar 1, 2025 | 1 year ago |
| SMA: Bullish | Feb 1, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 1, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 1, 2024 | 1 year ago |
| SMA: Bearish | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | Aug 1, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| MACD: Sell Signal | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Oct 1, 2023 | 3 years ago |
Newest 20 of 97.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.02 +10.2% upside
Now 20.89
- Target (low)
- 20.99
- Target (mean)
- 23.02
- Target (high)
- 25.99
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.24T | +3.7% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.14T | +4.1% | 0 |
| Current year | 148.67 | 51.16 – 246.19 | 61.00 | +143.7% | 4.71T | +695.6% | 2 |
| Next year | 198.63 | 138.53 – 258.73 | 148.67 | +33.6% | 4.81T | +2.1% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | TD Cowen | Maintained | Outperform | Outperform |
| Apr 4, 2023 | TD Cowen | Maintained | — | Outperform |
| Mar 16, 2023 | B of A Securities | Upgrade | Neutral | Buy |
| Jul 19, 2022 | Cowen & Co. | Upgrade | Market Perform | Outperform |
| Oct 7, 2021 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Mar 11, 2020 | JP Morgan | Maintained | — | Overweight |
| Nov 1, 2019 | Cowen & Co. | Initiated | — | Market Perform |
| Sep 24, 2019 | Jefferies | Initiated | — | Buy |